Epinastine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Ophthalmic
Allergic conjunctivitis

Adult: As 0.05% soln: Instill 1 drop into each eye bid.
Child: ≥12 yr Same as adult dose.

Special Precautions

Pregnancy and lactation.

Adverse Reactions

Nervous: Headache.
GI: Taste disturbance.
Resp: Upper resp infection, cough, rhinitis, sinusitis, pharyngitis.
Ophthalmologic: Burning sensation, folliculosis, conjunctival hyperaemia, dryness, pain, pruritus, increased lacrimation, visual disturbance.

Pregnancy Category (US FDA)

Ophth: C

Patient Counseling Information

Remove contact lenses prior to instillation and may be reinserted after 10-15 min.

Action

Description: Epinastine, a selective H₁-receptor antagonist, inhibits the release of histamine from mast cells. It also possesses affinity to H₂, α₁, α ₂, and 5-HT₂ receptors.
Onset: 3-5 min.
Duration: 8 hr.
Pharmacokinetics:
Absorption: Minimal systemic absorption after topical application. Time to peak plasma concentration: Approx 2 hr.
Distribution: Volume of distribution: 417 L. Plasma protein binding: 64%.
Metabolism: >10% is metabolised.
Excretion: Via urine (as unchanged drug). Terminal elimination half-life: 12 hr.

Chemical Structure

Storage

Store between 20-25°C.

MIMS Class

Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories

ATC Classification

S01GX10 - epinastine ; Belongs to the class of other ophthalmologic antiallergics.

References

Anon. Epinastine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/02/2017.

Buckingham R (ed). Epinastine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/02/2017.

Epinastine Hydrochloride Solution (Apotex Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/02/2017.

Joint Formulary Committee. Epinastine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/02/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Epinastine Hydrochloride (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 28/02/2017.

Disclaimer: This information is independently developed by MIMS based on Epinastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com